Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults
HIV Infections
About this trial
This is an interventional prevention trial for HIV Infections focused on measuring Vaccines, Synthetic, Viral Vaccines, HIV Antibodies, HIV Envelope Protein gp160, AIDS Vaccines, T-Lymphocytes, Cytotoxic, HIV Seronegativity, Antibody Formation, Risk-Taking, Avipoxvirus, Genetic Vectors, Immunization, HIV Preventive Vaccine
Eligibility Criteria
Inclusion Criteria You may be eligible for this study if you: Are 18-60 years old. Are HIV-negative and are in good health. Have a CD4 count of at least 400 cells/mm3. Test negative for hepatitis B. Agree to use effective methods of birth control for 1 month before and during the study. Exclusion Criteria You will not be eligible for this study if you: Are at high risk for being infected with HIV (risky sex behavior or injection drug use within 12 months prior to study entry). Have a serious medical condition, or if you have had chronic sickness, diseases of the immune system, or cancer that was not cured through surgery. Have a serious psychiatric condition or if you have been suicidal. Have a work commitment that would keep you from completing the study. Have syphilis or tuberculosis. Are allergic to eggs, neomycin, vaccines, or have ever had severe allergic reactions. Have taken certain medicines, including medicines that affect the immune system or experimental medicines. Have participated in another HIV vaccine trial. Have received any vaccines within 2 weeks of study entry. Have received a blood transfusion within 6 months prior to study entry. Are pregnant or breast-feeding.
Sites / Locations
- UAB AVEG
- JHU AVEG
- St. Louis Univ. School of Medicine AVEG
- Univ. of Rochester AVEG
- Vanderbilt Univ. Hosp. AVEG
- UW - Seattle AVEG